![]() |
市场调查报告书
商品编码
1383352
到 2030 年电泳市场预测:按产品、应用、最终用户和地区分類的全球分析Electrophoresis Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography |
根据Stratistics MRC的数据,2023年全球电泳市场规模为31亿美元,预计2030年将达到52.1亿美元,预测期内复合年增长率为7.7%。
可以使用称为电泳的方法分离蛋白质和核酸。电泳耗材和设备的主要用途是DNA和RNA分析。此外,它还用于生物化学领域,透过电荷、大小和亲和性来分离分子。它也用于根据大小、纯度和密度等因素分离蛋白质。该技术的易用性使其可用于许多任务,包括疫苗分析、抗体分析、血红蛋白疾病诊断和药物品管。
根据 PharmaTimes 2018 年 12 月号报道,2018 年前 10 个月,生技部门的创业投资投资额为 135 亿美元,超过了 2017 年创下的 110 亿美元的全年纪录。
在生物技术和生命科学研究中,电泳对于基因组序列测定至关重要。电泳可以分离和分析 DNA 片段,为次世代定序方法的进步铺平了道路。此外,蛋白质体分析对于帮助了解疾病、药物开发和生物标记发现至关重要。所有这些领域都增加了对先进电泳系统的需求。
电泳步骤的复杂性是该领域的主要障碍之一。设定和运行准确的电泳实验需要一定程度的技能。此外,未经专门培训的研究人员可能难以解释结果或解决问题,这可能会限制他们进行研究。
高通量电泳系统有一个强大的市场,特别是在蛋白质体学和基因组学等领域。此外,更快、更有效率系统的开发将使研究人员能够在更短的时间内分析更大的样本集,从而大大增加研究人员的机会。这可能会导致学术研究、製药和临床诊断领域的更多采用。
电泳市场面临的问题是负担能力。电泳设备、电源以及凝胶和缓衝液等消耗品的初期成本较高,可能妨碍它们在小型实验室或资源有限的环境中使用。此外,对消耗品的持续需求增加了整体成本,因此为了保持竞争力,製造商必须创新并开发更实惠的解决方案。
电泳市场受到COVID-19大流行的显着影响。全球供应链已中断,影响了电泳消耗品和设备的可用性。然而,技术在诊断测试开发中发挥的重要作用也受到关注,特别是在 PCR 检测等测试的快速生产和检验中。此外,在全球卫生紧急情况下,疫情凸显了电泳在疫苗研究和感染疾病研究中的价值,为该产业开闢了新的业务前景。
在预测期内,电泳软体预计将占据电泳市场的最大份额。在巨量资料时代,这些软体解决方案对于电泳结果的资料管理、解释和分析至关重要。它透过确保准确和可重复的结果来提高研究和诊断的有效性,并且在基因组学、蛋白质组学和临床应用中特别有用。此外,电泳软体正在成为电泳市场的支柱,并且由于其自动化资料处理和提供有洞察力的资讯的能力而变得越来越重要。
在电泳市场中,製药和生物技术公司预计将表现出最高的复合年增长率。这些公司不断推动对电泳服务和设备的需求,因为他们将电泳用于多种目的,包括生技药品分析、品管和药物开发。此外,该市场强劲而稳定的成长部分归因于对生物製药的日益关注以及对复杂生物分子准确表征的需求。他们在研发方面的领先地位使製药和生物技术公司成为电泳领域创新和市场拓展的主要力量。
北美占据全球电泳市场最大份额。造成这一优势的因素有很多,包括强大的医疗保健系统、大量的研发投资、慢性病的高盛行率以及生物技术和製药公司的集中。此外,该地区庞大的市场占有率也归功于其强大的学术研究机构和对技术进步的关注。透过积极实施最尖端科技和严格的监管要求,我们在北美电泳市场的领导地位得到进一步加强。
在全球电泳市场中,亚太地区的复合年增长率最高。许多因素促成了这种快速增长,包括生物技术和製药行业的活性化、研究和开发的增加、对精准医疗的重视以及学术和研究机构数量的增加。此外,市场的强劲扩张还得益于该地区医疗基础设施的不断扩大以及对尖端诊断技术的需求。因此,亚太地区正在显着成长,并成为电泳市场中更重要的参与企业。
According to Stratistics MRC, the Global Electrophoresis Market is accounted for $3.1 billion in 2023 and is expected to reach $5.21 billion by 2030 growing at a CAGR of 7.7% during the forecast period. Proteins and nucleic acids can be separated using an approach called electrophoresis. The primary uses of electrophoresis supplies and equipment are in the analysis of DNA and RNA. Additionally, it is employed in biochemistry to separate molecules according to their charge, size, or affinity. And it is used to separate proteins according to factors such as size, purity, and density. This technique's ease of use makes it useful for a number of tasks, including vaccine analysis, antibody analysis, hemoglobinopathies diagnosis, and drug quality control.
According to PharmaTimes December 2018, 13.5 bn USD venture capital was invested into the biotechnology sector in the first ten months of 2018, beating the previous full-year record of USD 11 bn in 2017.
In biotechnology and life sciences research, electrophoresis is essential for genomic sequencing. It allows DNA fragments to be separated for analysis and opens the door for advancements in next-generation sequencing methods. Furthermore, it is essential for proteomic profiling, which aids in the understanding of diseases, drug development, and biomarker discovery. All of these areas have a greater need for sophisticated electrophoresis systems.
The complicated nature of the procedures involved in electrophoresis is one of the major obstacles in the field. Accurate experiment setup and execution in electrophoresis demand a certain level of skill. Moreover, researchers without specialized training may find it difficult to interpret the results and troubleshoot any issues, which can limit their accessibility.
There is a strong market for high-throughput electrophoresis systems, particularly in areas like proteomics and genomics. Additionally, researcher opportunities can be greatly increased by the development of faster and more efficient systems, which will make it possible to analyze larger sample sets in less time. Increased adoption in academic research, pharmaceuticals, and clinical diagnostics may result from this.
The issue of affordability faces the electrophoresis market. Due to the high initial cost of electrophoresis equipment, power supplies, and consumables like gels and buffers, smaller research labs and environments with limited resources may not be able to use them. Moreover, to remain competitive, manufacturers must innovate and develop more affordable solutions because the continuous need for consumables raises the overall cost.
The market for electrophoresis was greatly affected by the COVID-19 pandemic. The global supply chain was disrupted, which affected the availability of consumables and equipment for electrophoresis. However, it also brought attention to the crucial role that technology plays in the development of diagnostic tests, especially in the quick creation and validation of tests like PCR assays. Furthermore, in the context of international health emergencies, the pandemic highlighted the value of electrophoresis in vaccine research and the study of infectious diseases, opening up new business prospects for the industry.
Over the course of the forecast period, electrophoresis software is expected to hold the largest share in the electrophoresis market. In the big data era, these software solutions are essential for managing, interpreting, and analyzing data from electrophoresis results. They improve the effectiveness of research and diagnostics by guaranteeing precise and repeatable results, which is especially useful in genomics, proteomics, and clinical applications. Moreover, electrophoresis software is becoming a central and increasingly important part of the electrophoresis market because of its capacity to automate data handling and offer insightful information.
In the electrophoresis market, the Pharmaceutical & Biotechnology Companies segment is projected to have the highest CAGR. These businesses constantly drive demand for electrophoresis services and equipment because they use electrophoresis for a variety of purposes, such as biologics analysis, quality control, and drug development. Additionally, the robust and steady growth seen in this market is partly due to the increased focus on biopharmaceuticals and the requirement for accurate characterization of complex biomolecules. Due to their leadership in research and development, pharmaceutical and biotechnology companies are a major force behind innovation and market expansion in the electrophoresis sector.
In the global electrophoresis market, North America holds the largest share. Numerous factors, including a robust healthcare system, large investments in R&D, a high rate of chronic illnesses, and a large concentration of biotechnology and pharmaceutical companies, are responsible for this dominance. Moreover, the substantial market share of the region can be attributed to its strong academic and research institutions, as well as its emphasis on technological advancements. North America's leadership in the electrophoresis market is further cemented by its proactive adoption of cutting-edge techniques and strict regulatory requirements.
In the global electrophoresis market, Asia-Pacific is growing at the highest CAGR. Numerous factors, including the growing biotechnology and pharmaceutical industries, more R&D being done, an increasing emphasis on precision medicine, and an increase in academic and research institutions, are contributing to this rapid growth. Additionally, the strong market expansion is also attributed to the region's expanding healthcare infrastructure and the demand for cutting-edge diagnostic technologies. As a result, Asia-Pacific is growing significantly and is becoming a more significant player in the electrophoresis market.
Some of the key players in Electrophoresis market include: Cleaver Scientific Ltd., Analytik Jena GMBH, Lumex Instruments , Beckman Coulter, Agilent Technologies, Inc., QIAGEN N.V., Sebia Group, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Hoefer, Inc. (Harvard Biosciences), Danaher Corporation, Merck & Co. Inc., Takara Bio, Inc., AES life sciences, Helena Laboratories Corporation, PerkinElmer Inc., SERVA Electrophoresis GmbH, Lonza Group and Shimadzu Corporation.
In August 2023, Collaboration between Beckman Coulter and Fujirebio is expected to lead to multiple new tests for neurodegenerative diseases, including Alzheimer's. The new collaboration, which was announced last month, builds on the supplier relationship between the two companies that has existed for more than 20 years, said Monte Wiltse, president and CEO of Fujirebio Diagnostics.
In April2023, Ohio Lumex Signs Agreement With Mississippi Lime Company (MLC) to Take Over Customer and Technical Services for Breen. MLC grants license to Ohio Lumex to sell and service Breen sulfuric acid dewpoint monitoring technologies. Mississippi Lime Company (MLC), a leading global supplier of high-calcium lime products and technical solutions, has completed an agreement to transfer customer and technical services for its Breen Energy Solutions subsidiary to Ohio Lumex.
In March 2023, Agilent Technologies Inc. today announced a multi-year distribution agreement with Proscia® a leader in digital pathology - to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq® Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes.